Research · Sep 3, 2026
[ITGR] Integer Holdings Thesis 2026: Medical-Device Contract Manufacturer Cardio Neuro Compounder
Integer Holdings Corp (NYSE: ITGR), headquartered in Plano-TX, is a Medical-Device-Contract-Manufacturer-Cardio-and-Neuromodulation + emerging-multi-cycle-Medical-Device-Outsourcing-and-Cardio-and-Neuro-and-Vascular leader providing distinctive multi-cycle Cardio-Rhythm-and-Neuromodulation-OEM-Components + emerging-Vascular + emerging-PFA-Pulsed-Field-Ablation + emerging-Structural-Heart + emerging-Neuromodulation-Pain-and-Movement-Disorder + emerging-Diagnostics-and-Drug-Delivery services to substantial multi-cycle Medtronic-and-Boston-Scientific-and-Abbott-and-Stryker-and-Edwards-Lifesciences-and-Johnson-Johnson-MedTech-OEM-Customer + multi-cycle-emerging-PFA-Cardio-Ablation-and-Renal-Denervation-OEM-Customer + multi-cycle-emerging-Neuromodulation-Pain-and-Movement-Disorder-OEM + multi-cycle-emerging-Structural-Heart-and-TAVR-OEM customer base. The company has distinctive multi-cycle Integer-Holdings-and-Plano-TX-and-Medical-Device-Contract-Manufacturer heritage: founded 2016 as Integer-Holdings-via-Greatbatch-Lake-Region-Medical-merger ($1.8B providing Cardio-Rhythm-and-Vascular-and-Neuromodulation-Components-Outsourcing-Scale + Wayne-Township-PA-historical-1970-founded-Greatbatch + Florida-Lake-Region-Medical-2008-founded-history); 2016 substantial NYSE Integer-Holdings-IPO-rename; 2018 substantial Advanced-Surgical-Acquired-Strategic-Divest ($600M divest providing focus-on-Cardio-Rhythm-and-Vascular-and-Neuromodulation); 2020 substantial Inomec-Drug-Delivery-acquired ($235M providing Drug-Delivery-and-Diagnostics-Adjacency); 2022 substantial Connemara-Medical-Devices-acquired ($55M providing Vascular-Catheter-Outsourcing); 2022 substantial Aran-Biomedical-acquired ($80M providing Cardio-Rhythm-and-Vascular-Catheter-Outsourcing); 2023 substantial InNeuroCo-acquired (providing Cardio-Rhythm-and-Vascular-Catheter-Outsourcing); 2024 substantial Pulse-Technologies-acquired ($142M providing Cardio-Rhythm-PFA-and-Structural-Heart-Outsourcing); 2024 substantial VSi-Parylene-acquired ($30M providing Vascular-Catheter-Coating); multi-cycle-disciplined-Cardio-and-Neuro-and-Vascular-Outsourcing-acquisitions; Joseph-Dziedzic-CEO + Tom-Hook-Former-CEO-leadership-succession-2017. FY2025 closes with selected various aggregate revenue ~$1.80-1.95B (~6-10% YoY-reflecting Medical-Device-Outsourcing-Demand + emerging-multi-cycle-Cardio-Rhythm-and-Neuromodulation-Cycle + emerging-PFA-Pulsed-Field-Ablation-Outsourcing-Ramp + emerging-Renal-Denervation-Adjacency), adjusted EBITDA ~$345-420M (~18-22% margins), adjusted EPS ~$5.40-6.50 (steady-Medical-Device-Outsourcing-margin-execution), net debt ~$0.85-1.05B (~2.4-3.0x leverage), and ~33-34M shares outstanding under President & CEO Joseph Dziedzic (since-2017). The Cardio-Rhythm-and-Neuromodulation-and-Vascular-and-PFA-Outsourcing franchise deep-dive covers distinctive multi-cycle ~9,800+ employees + ~Plano-TX-HQ + ~Frisco-TX-Wayne-Township-PA-Galway-Ireland-Tijuana-Mexico-Globally-Positioned-Medical-Device-Outsourcing-Manufacturing-Facility, CR&NM ~70-75% revenue + C&V ~22-27% revenue + AS&O ~3-7% revenue, substantial multi-cycle Medtronic ~26-30% revenue + Boston-Scientific ~15-20% + Abbott ~10-14% OEM-Customer-base, 2016-NYSE-Greatbatch-Integer-IPO-rename + 2020-Inomec-Drug-Delivery + 2022-Connemara-and-Aran-Biomedical + 2023-InNeuroCo + 2024-Pulse-Technologies-and-VSi-Parylene transformational-platform, emerging-multi-cycle Cardio-Rhythm-and-Neuromodulation-Outsourcing-Demand + emerging-PFA-Pulsed-Field-Ablation-Outsourcing-Ramp + emerging-Renal-Denervation-Adjacency + emerging-Structural-Heart-and-TAVR-Outsourcing + emerging-Neuromodulation-Pain-and-Movement-Disorder-Cycle + emerging-Diagnostics-and-Drug-Delivery-Adjacency structural-tailwinds, competing in Medical-Device-Contract-Manufacturer space with Heraeus-Medical-Components, Phillips-Medisize/Molex/Koch, West Pharmaceutical Services, Gerresheimer, Nordson MEDICAL, Marox/MicroPort/Resonetics, Stevanato Group, AptarGroup, Datwyler; and private-equity-Carlyle-Apollo-KKR-Blackstone-CD&R-EQT-Bain-Veritas-Genstar-Permira-Investindustrial-CVC-Bridgepoint-Cinven-Ardian-TPG-CCMP-Vista-Insight-General-Atlantic. The Joseph-Dziedzic + 2017-CEO-succession + multi-decade compounder thesis + 2016-Greatbatch-Lake-Region-Medical-merger-and-2024-Pulse-Technologies deep-dive covers Joseph-Dziedzic-CEO (since-2017, ~8 year longtime-Integer-CEO + Former-Greatbatch-CFO + Former-Lincoln-Electric-CFO) expertise, 2016-Greatbatch-Lake-Region-Medical-merger-rename-Integer-Holdings + 2018-Advanced-Surgical-Divest + 2020-Inomec-Drug-Delivery + 2022-Connemara-and-Aran-Biomedical + 2023-InNeuroCo + 2024-Pulse-Technologies ($142M) + 2024-VSi-Parylene transformational-M&A platform, no-dividend (Cash-Flow-Reinvested-in-Cardio-and-Neuro-and-Vascular-M&A) + multi-cycle-emerging-share-buyback-only (~$50-150M/yr discretionary). Capital position is IG-equivalent (Baa3/BBB- ~2.4-3.0x leverage). At ~$110-160 per share, equity value ~$3.65-5.35B, EV ~$4.50-6.40B, providing ~18-26x EPS and ~12-17x EV/EBITDA.